Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Clinical Case 2 Scenario

December 13th 2021

Drs In and Emerick analyze the data from our second clinical case scenario and tell us what they would do if it were their patient.

Radiation Approaches for CSCC and Standard of Care

December 13th 2021

Dr Bakst comments on radiation treatment therapies and the standard of care for cutaneous squamous cell carcinoma.

Dr. Lipson on the Role of ctDNA Testing in Melanoma

December 8th 2021

Evan J. Lipson, MD, discusses the role of circulating tumor DNA ​testing in melanoma.

FDA Greenlights Companion Diagnostic for BRAF Inhibitors in Melanoma

December 8th 2021

The FDA has approved FoundationOne CDx for use as a companion diagnostic for 2 groups of current a future regulatory-approved treatments in melanoma, including single-agent BRAF inhibitors targeting BRAF V600E mutations and BRAF/MEK combination regimens targeting BRAF V600E or V600K mutations.

Incidence of Cutaneous Squamous Cell Carcinoma

December 6th 2021

Starting the discussion on cutaneous squamous cell carcinoma, Dr Emerick provides insight on signs to look for, as well as risk factors.

Immunotherapy in Basal Cell Carcinoma

December 6th 2021

Two experts provide their thoughts on phase 2 data concerning the use of cemiplimab for treating locally advanced basal cell carcinoma.

Ripretinib Demonstrates Impressive Efficacy, Durability in Heavily Pretreated KIT-Mutated Melanoma

December 6th 2021

Filip Janku, MD, PhD, discusses the phase 1 study with ripretinib in patients with KIT-mutated or KIT-amplified melanoma.

FDA Approves Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma Following CR

December 3rd 2021

The FDA has approved pembrolizumab for the adjuvant treatment of adult and pediatric patients with stage IIB or IIC melanoma following complete resection.

Tebentafusp Represents a Potential Frontline Therapy for Patients with Uveal Melanoma

December 2nd 2021

Richard D. Carvajal, MD, discusses the need for additional treatment options in patients with rare melanomas, the promise of tebentafusp, and ongoing trials in the pipeline for this patient population.

Dr. Luke on Toxicities With Targeted Therapy Vs Immunotherapy in Melanoma

December 1st 2021

Jason J. Luke, MD, FACP, discusses the toxicities with targeted therapy vs immunotherapy and management strategies for patients with melanoma. 

BO-112 Plus Pembrolizumab Improves ORR in Advanced Melanoma After Progression on Anti–PD-1 Therapy

December 1st 2021

The addition of BO-112 to pembrolizumab produced clinical benefit in patients with unresectable malignant melanoma who have experienced disease progression on anti–PD-1 therapy, according to data from the preliminary analysis of the phase 2 SPOTLIGHT-203 trial.

Hedgehog Inhibitors and Basal Cell Carcinoma

November 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, and Gino K. In, MD, MPH, elaborate on the role hedgehog inhibitors can play when treating patients with basal cell carcinoma.

Treatment Options for Basal Cell Carcinoma

November 30th 2021

Drs Emerick and Bakst continue to speak on the data from the first clinical case scenario and highlight other treatment options.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

November 24th 2021

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial with relatlimab and nivolumab, and the phase 3 KEYNOTE-716 trial with pembrolizumab, cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes.

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

November 23rd 2021

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Clinical Presentation of Basal Cell Carcinoma

November 22nd 2021

Richard Bakst, MD, and Ezra Cohen, MD, FRCPSC, FASCO, explain what the typical clinical presentation of basal cell carcinoma will look like in a patient.

Clinical Case 1 Scenario and Surgical Options for Basal Cell Carcinoma

November 22nd 2021

Kevin Emerick, MD, analyzes the data from the first clinical case scenario and touches upon potential surgical options for patients with similar diagnoses.

Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With Cancer

November 19th 2021

Caroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.

Patients with RCC, Melanoma Taking ICIs Can Safely Receive COVID-19 Vaccination

November 15th 2021

The COVID-19 vaccine was safe and well tolerated in patients who received immune checkpoint inhibitors for renal cell carcinoma or melanoma.